TY - CHAP M1 - Book, Section TI - Osteoclast-Targeted Therapy: Bisphosphonates and Denosumab A1 - Smith, Matthew R. A2 - Chabner, Bruce A. A2 - Longo, Dan L. PY - 2016 T2 - Harrison's Manual of Oncology, 2e AB - Bone metastases are a major cause of morbidity in patients with a variety of malignancies including multiple myeloma, breast cancer, and prostate cancer (1). Bone metastases are often described as osteoblastic or osteolytic based on their radiographic appearance. Osteoblastic and osteolytic bone disease represent two extremes of a spectrum, however, and osteoclast number and activity are increased in most bone metastases, including typical osteoblastic metastases from prostate cancer. Pathological activation of osteoclasts appears to play a central role in disease-related skeletal complications. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/14 UR - hemonc.mhmedical.com/content.aspx?aid=1127647081 ER -